What Pier88 Health does

Pier88 Health (杭州彼爱方好科技有限公司 / BiAi Medical, consumer brand 疼爱健康 / Tengai Health) is a Hangzhou-based digital health company founded in 2018 that builds AI- and big-data-driven software for the diagnosis, treatment, and ongoing management of headache and migraine. Its core platform is a two-sided product: the 疼爱健康 WeChat mini-program targets patients with intelligent head-and-facial-pain assessment, medical guidance, expert online consultation, digital therapeutics, and electronic headache diaries, while the 医者无界 (YiZhe WuJie) mobile app targets neurology, pain, and internal-medicine physicians with electronic medical records, online consultation and prescribing, patient follow-up tools, and clinical research support. The business is augmented by the 疼爱精选 e-commerce mini-program for doctor-recommended products.

The company's monetization model combines software subscriptions and service fees (patient platform, physician platform, pharma clinical-trial support, employer headache-productivity programs) with hardware sales. In 2024 Pier88 Health secured an exclusive China strategic partnership for Nerivio (纳瑞维), an Israeli remote electrical nerve modulation (REN) migraine device from Bio Therapeutics, which is being rolled out first through the Hainan Boao Lecheng International Medical Pioneer Zone and is targeted for a nationwide China launch in H2 2024. The addressable market is anchored at China's roughly 130 million migraine patients, with secondary exposure to pharmaceutical/medtech sponsors and employer organizations seeking to reduce headache-driven absenteeism and disability costs.

As of the most recent data points, Pier88 Health operates with an 11–50 employee team out of its headquarters in Hangzhou's Binjiang district, has raised $6M in a Series 4 round from Tibet AIM Pharm in February 2023, and discloses no revenue, ARR, or active user metrics. The founding and executive team is drawn from Microsoft, Accenture, Morningstar, and higi, and the medical advisory team includes physicians from Stanford University Medical Center and the University of California Medical Center. The company is privately held with no identified parent or external institutional investor beyond Tibet AIM Pharm.

Name

Pier88 Health

Legal name

杭州彼爱方好科技有限公司 (Hangzhou BiAi FangHao Technology Co., Ltd.)

Website

https://p88health.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Pier88 Health is a Hangzhou-based digital health company founded in 2018 that builds AI-driven platforms for headache and migraine management, serving China's 130 million migraine patients via the 疼爱健康 mini-program and physicians via the 医者无界 app, with exclusive China rights to the Nerivio REN device.

Ownership category

akta.pro rank

Product category

Digital Health Headache & Migraine Management

NAICS

Social Assistance (624), Computer Systems Design and Related Services (54151)

SIC

Services-Health Services (8000), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Headache & Migraine Medicine (HLAKAIAE)

akta.pro secondary industries

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Digital health platform
• Headache management
• Migraine treatment
• Remote nerve modulation
• Telemedicine services

Headquarters

HQ city

Binjiang

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. Digital Health Services: Platform provides digital health management services including intelligent assessment, expert consultations, and digital therapeutics through mini-programs and apps. Revenue generated from service fees to patients and physicians.
2. Medical Device Sales - Nerivio: As the exclusive strategic partner for Nerivio (Israeli remote electrical nerve modulation device for migraine treatment) in China, Pier88 Health generates revenue from the sale of this prescription medical device for both acute and preventive migraine treatment.
3. Healthcare Professional Platform Services: The '医者无界' App provides digital tools for physicians including electronic medical records, online consultation, patient management, and clinical research support. Revenue from professional services and subscriptions for healthcare providers.
4. Enterprise Health Solutions: Services targeting employer organizations to manage employee headache-related productivity loss and disability, including educational content, medical resources, and therapy recommendations.
5. Pharma/Medtech Clinical Trial Services: Digital tools and data collection services provided to pharmaceutical and medical device companies for clinical trial support, reducing screening failure rates and improving patient compliance in research studies.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Pier88 Health operates an AI- and big data-driven digital health platform for headache and migraine management, delivering a patient-facing WeChat mini-program (疼爱健康/Tengai Health) that provides intelligent pain assessment, expert online consultations, digital therapeutics, electronic headache diaries, and lifestyle/dietary supplement recommendations. It also offers a physician-facing mobile app (医者无界/Yizhe Wujie) with electronic headache records, online consultation/prescribing, patient follow-up management, and clinical research support. In parallel, the company is the exclusive China strategic partner for Nerivio, an Israeli prescription remote electrical nerve modulation (REN) device for acute and preventive migraine treatment.

Product overview

Pier88 Health operates as a platform-plus-modules architecture with two primary products targeting different user segments: (1) 疼爱健康 (Tengai Health) mini-program for patients providing head pain intelligent assessment, medical guides, expert consultations, and electronic headache logs; and (2) 医者无界 (Yizhe Wujie) App for physicians providing international academic content, electronic medical records, online consultations, and clinical research tools. The platform also includes 疼爱精选 e-commerce module for recommended health products and integrates Nerivio (纳瑞维), an Israeli remote electrical nerve stimulation device for migraine treatment. All offerings are powered by AI and big data with evidence-based medicine at the core, serving China's 130 million migraine patients and healthcare professionals.

Differentiator

Problem solved

Functional benefit

Brands

• 疼爱健康 (TengAi Health): Digital intelligent platform for chronic pain management, focusing on headache and migraine. Provides head and facial pain intelligent assessment, headache medical guide, expert online consultation, cutting-edge medication/device recommendations, professional dietary supplements, and digital management full-course management solutions for patients.
• 医者无界 (YiZhe WuJie)

Products and services

• 疼爱健康 (Tengai Health) WeChat Mini-Program Patient-facing AI-powered WeChat mini-program that delivers full-course headache management for individual migraine and chronic-headache patients, including intelligent head-and-face pain assessment, headache medical guide, expert online consultations, cutting-edge medication and device recommendations, professional dietary supplements, evidence-based digital therapeutics, and an electronic headache diary. Available via WeChat to Chinese consumers.
• 医者无界 (Yizhe Wujie) Mobile App Physician-facing mobile application for licensed Chinese medical professionals (neurology, pain, internal medicine, general practice, plus medical students) that provides international academic headache content, electronic headache medical records, online consultation and prescribing, patient follow-up management, and clinical research support.
• 疼爱精选 (Tengai Selection) E-commerce Mini-Program Shopping mini-program that offers doctor-recommended headache relief products and emergency care gift boxes, integrated with the 疼爱健康 patient ecosystem as a product commerce channel.
• Nerivio (纳瑞维) Remote Electrical Nerve Modulation Device Prescription, self-managed, home-use remote electrical nerve modulation (REN) device for acute and preventive treatment of migraine with or without aura in patients aged 12 and older; distributed in China by Pier88 Health under exclusive partnership with the Israeli manufacturer.

Quantifiable outcome

• 130 million potential migraine patients in China as target market
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration13 records

AI capability6 records

Feature5 records

Partnerships

One partnership is on record.

• Nerivio (Bio Therapeutics/Israel)coreStrategic or Co-development Partner · 1 January 2024Pier88 Health is the exclusive strategic partner in China for Nerivio, an Israeli remote electrical nerve modulation (REN) device for migraine treatment. Nerivio (Chinese name: 纳瑞维) is suitable for acute and preventive treatment of migraine with or without aura in patients aged 12 and above. The device is a prescription, self-managed home-use device. Pier88 Health serves as the exclusive channel partner responsible for market entry, distribution, and promotion of Nerivio in mainland China. The device is expected to officially launch in China in H2 2024, with early access available at Hainan Boao Lecheng International Medical Pioneer Zone.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Click Therapeutics: Digital therapeutics platform developing prescription software for chronic conditions including migraine. Operates a software-plus-pharma-partnership model that mirrors Pier88's pharma/medtech clinical trial services revenue line.
• Better Therapeutics: Prescription digital therapeutics developer for cardiometabolic conditions. Similar profile as a venture-stage DTx company targeting a large chronic-disease population with software-led therapy.
• Akili Interactive: FDA-cleared prescription digital therapeutics company. Comparable as a digital therapeutics platform with regulatory clearances that pairs software with clinical outcomes — same DTx model Pier88 is pursuing for migraine in China.
• Pear Therapeutics: Pioneer in prescription digital therapeutics for chronic conditions. Closely comparable business model of combining regulated software with clinical evidence to drive physician adoption and payer reimbursement.
• electroCore: Developer of gammaCore, a non-invasive vagus nerve stimulation device for migraine and cluster headache. Directly comparable as a neuromodulation device company targeting the same migraine indication as Pier88's Nerivio.
• Big Health: Digital therapeutics company behind Sleepio and Daylight for chronic sleep and anxiety conditions. Comparable as a chronic-condition digital therapeutics company selling to employers, payers, and consumers.

Broad incumbents

• WeDoctor: Major Chinese online healthcare platform combining telehealth, physician networks, and chronic disease management. Compares as a broad incumbent that could move into headache specialty services.
• Ping An Healthcare and Technology: Largest Chinese telehealth and digital health platform with broad chronic-condition coverage. Overlaps with Pier88 in Chinese digital health delivery but operates as a horizontal incumbent rather than a headache-vertical specialist.

Emerging players

• Theranica Bio-Electronics: Israeli maker of Nerivio, the remote electrical nerve modulation device Pier88 distributes in China. Comparable as a migraine-focused neuromodulation device company and Pier88's exclusive device partner globally.
• Healint (Migraine Buddy): Developer of Migraine Buddy, the world's largest migraine tracking app with millions of users. Comparable as a digital, data-driven headache-management platform, though more patient-focused and lacking the prescription-device and physician channels Pier88 operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pier-88-health-inc.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pier88 Health